TY - JOUR
T1 - Endovascular repair of abdominal aortic aneurysms
T2 - Initial experience with 100 consecutive patients
AU - Elkouri, Stephane
AU - Gloviczki, Peter
AU - McKusick, Michael A.
AU - Panneton, Jean M.
AU - Andrews, James C.
AU - Bower, Thomas C.
AU - Noel, Audra A.
AU - Sullivan, Timothy M.
AU - Canton, Linda G.
AU - Harmsen, William S.
AU - Hoskin, Tanya L.
AU - Cherry, Kenneth J.
PY - 2003/10/1
Y1 - 2003/10/1
N2 - Objective: To review early results of endovascular repair of abdominal aortic aneurysms (AAAs). Patients and Methods: The first 100 patients who underwent endovascular repair of AAA (EVAR) between June 26, 1996, and October 31, 2001, at the Mayo Clinic in Rochester, Minn, were studied retrospectively to evaluate technical success, freedom from reinterventions, and early clinical outcome. Results: A total of 89 men and 11 women (mean ± SD age, 76±7 years; range, 47-92 years) underwent EVAR. The procedure was successful in 97 patients. There was no early death. Major complications occurred in 25 patients. The 30-day technical success rate was 86% (95% confidence interval [CI], 77%-92%). The median intensive care unit stay was 1 day (range, 1-15 days), and the median hospital stay was 3 days (range, 1-35 days). Median follow-up was 7 months (range, 1-60 months). Endoleak (incomplete seal of the endovascular graft) at discharge was observed in 14 patients; 13 developed endoleak during follow-up. There were 23 reinterventions, 65% of which were percutaneous procedures. One aneurysm ruptured at 5 months, but the patient was successfully treated by open repair. Primary and secondary graft patency rates at 1 year were 83% (95% CI, 74%-93%) and 94% (95% CI, 87%-99%), respectively. The freedom from reintervention rate at 1 year was 71% (95% CI, 59%-84%), with an overall success rate from EVAR of 92% (95% CI, 84%-100%). There were no differences in early patency, reinterventions, and success rates between unibody and modular devices. Conclusion: EVAR can be performed with high technical success and low mortality rates; however, nonfatal complications and catheter-based reinterventions are frequent, and EVAR may not prevent aneurysm rupture. Although stent graft repair for high-risk patients is appealing, current data are insufficient to support EVAR as the preferred treatment of AAAs.
AB - Objective: To review early results of endovascular repair of abdominal aortic aneurysms (AAAs). Patients and Methods: The first 100 patients who underwent endovascular repair of AAA (EVAR) between June 26, 1996, and October 31, 2001, at the Mayo Clinic in Rochester, Minn, were studied retrospectively to evaluate technical success, freedom from reinterventions, and early clinical outcome. Results: A total of 89 men and 11 women (mean ± SD age, 76±7 years; range, 47-92 years) underwent EVAR. The procedure was successful in 97 patients. There was no early death. Major complications occurred in 25 patients. The 30-day technical success rate was 86% (95% confidence interval [CI], 77%-92%). The median intensive care unit stay was 1 day (range, 1-15 days), and the median hospital stay was 3 days (range, 1-35 days). Median follow-up was 7 months (range, 1-60 months). Endoleak (incomplete seal of the endovascular graft) at discharge was observed in 14 patients; 13 developed endoleak during follow-up. There were 23 reinterventions, 65% of which were percutaneous procedures. One aneurysm ruptured at 5 months, but the patient was successfully treated by open repair. Primary and secondary graft patency rates at 1 year were 83% (95% CI, 74%-93%) and 94% (95% CI, 87%-99%), respectively. The freedom from reintervention rate at 1 year was 71% (95% CI, 59%-84%), with an overall success rate from EVAR of 92% (95% CI, 84%-100%). There were no differences in early patency, reinterventions, and success rates between unibody and modular devices. Conclusion: EVAR can be performed with high technical success and low mortality rates; however, nonfatal complications and catheter-based reinterventions are frequent, and EVAR may not prevent aneurysm rupture. Although stent graft repair for high-risk patients is appealing, current data are insufficient to support EVAR as the preferred treatment of AAAs.
UR - http://www.scopus.com/inward/record.url?scp=0141593587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141593587&partnerID=8YFLogxK
U2 - 10.4065/78.10.1234
DO - 10.4065/78.10.1234
M3 - Article
C2 - 14531482
AN - SCOPUS:0141593587
SN - 0025-6196
VL - 78
SP - 1234
EP - 1242
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 10
ER -